AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12074415
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% with fentanyl 2 microg mL(‐1)
Trial: 2240994
Drug: Betahistine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (24 mg/day)
Trial: 7372228
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg digoxin b.i.d.
Trial: 7372228
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg digoxin b.i.d.
Trial: 7372228
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg beta-methyl-digoxin b.i.d.
Trial: 28071011
Drug: Isocaloric diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric diet plus metformin (IM)
Trial: 22282104
Drug: HeartMate II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HeartMate II (HMII) destination therapy (DT)
Trial: 18355402
Drug: Postmastectomy radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmastectomy radiotherapy plus systemic therapy (cyclophosphamide, methotrexate, and fluorouracil for premenopausal women; tamoxifen for postmenopausal women)
Trial: 12578439
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen of methylphenidate (3 times daily)
Trial: 10561294
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (non‐XRT group)
Trial: 1762298
Drug: Topical povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical povidone-iodine ointment (T)
Trial: 31869451
Drug: High-dose gabapentin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gabapentin (2700 mg daily) with standard care (hydrocodone and/or acetaminophen progressing to fentanyl as needed)
Trial: 31869451
Drug: Low-dose gabapentin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gabapentin (900 mg daily) with methadone
Trial: 30343354
Drug: Oral saffron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral saffron supplementation (20 mg/day) for 3 months
Trial: 30343354
Drug: Oral saffron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral saffron supplementation (20 mg/day) for 3 months among participants on AREDS supplements
Trial: 17686343
Drug: Cytotoxic monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic monoclonal antibodies (MAbs)
Trial: 16043407
Drug: Metoprolol tartrate
RxNorm normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metoprolol tartrate 50 mg bid
Trial: 8071837
Drug: BOF-4272 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOF-4272 100 mg
Trial: 8071837
Drug: BOF-4272 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOF-4272 200 mg
Trial: 8071837
Drug: BOF-4272 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOF-4272 400 mg
Trial: 8071837
Drug: BOF-4272 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOF-4272 200 mg (multiple-dose)
Trial: 8071837
Drug: Placebo (multiple-dose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (multiple-dose)
Trial: 30937510
Drug: Narrative Enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative Enhancement and Cognitive Therapy (NECT)
Trial: 21145258
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day plus placebo (ATV+PLA)
Trial: 21145258
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day plus allopurinol 300 mg/day (ATV+ALLO)
Trial: 16773859
Drug: Comprehensive assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive assessment followed by treatment
Trial: 16773859
Drug: Treatment without
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment without assessment
Trial: 16773859
Drug: Repetitive use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive use of ineffective treatments
Trial: 11361264
Drug: Nimesulide alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide alone (100 mg BD)
Trial: 11361264
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nimesulide (100 mg) and cetirizine (10 mg)
Trial: 11361264
Drug: Cetirizine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine alone (10 mg)
Trial: 8395721
Drug: Enoxaparin 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20 mg subcutaneously, administered 2 hours before surgery and each morning for 7 postoperative days (morning group)
Trial: 8395721
Drug: Enoxaparin 20
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 20 mg subcutaneously, administered the evening before surgery and postsurgically for 7 days in the evening (evening group)
Trial: 3512282
Drug: High-dose budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose budesonide (1600 micrograms per day)
Trial: 3512282
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose budesonide (400 micrograms per day)
Trial: 3512282
Drug: High-dose budesonide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose budesonide (1600 micrograms per day) during open-label phase
Trial: 18156171
Drug: Bortezomib monotherapy
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib monotherapy
Trial: 15366798
Drug: Pethidine 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine 0.8 mg/kg
Trial: 11344193
Drug: DHEA 50
RxNorm normalized name: Natrol Mood & Stress DHEA 50mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 50 mg/day
Trial: 2736882
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid solution supplemented with L‐alanyl‐L‐glutamine (Ala‐Gln) and glycyl‐L‐tyrosine (Gly‐Tyr)
Trial: 2736882
Drug: Control solution
RxNorm normalized name: Nausea Control Solution
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solution supplemented with alanine and glycine
Trial: 4881071
Drug: Tetracycline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (3 g or 4 g in one of 3 dose schedules)
Trial: 31383649
Drug: Ranibizumab (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.5 mg) administered as 3 monthly intravitreal injections followed by pro re nata at monthly visits
Trial: 26092310
Drug: Fully-liquid hexavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully-liquid hexavalent vaccine (DTaP-IPV-HB-PRP-T, Sanofi Pasteur MSD)
Trial: 26092310
Drug: Non-fully liquid
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-fully liquid hexavalent vaccine (DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals)
Trial: 26092310
Drug: Fully-liquid hexavalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully-liquid hexavalent vaccine
Trial: 23545009
Drug: BCG maintenance
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG maintenance therapy with one third of usual dose (group I)
Trial: 23545009
Drug: BCG maintenance
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG maintenance therapy with reduced dose and decreased number of instillations (two instead of three) (group II)
Trial: 11118822
Drug: Essential amino
RxNorm normalized name: Essential amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential amino acid (EAA) supplementation (average daily dose of 18.3 g of EAAs in pill form)
Trial: 9146772
Drug: Mesalazine suppositories
RxNorm normalized name: mesalamine Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine suppositories (1 g)
Trial: 9146772
Drug: Hydrocortisone foam
RxNorm normalized name: hydrocortisone Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone foam (100 mg)
Trial: 7816790
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (TA) for acute treatment, 200 mg at first symptoms, repeat after 2-3 hours if needed.
Trial: 7816790
Drug: Tolfenamic acid
RxNorm normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolfenamic acid (TA) for prophylactic treatment, 300 mg sustained release or 100 mg 3 times daily.
Trial: 2905992
Drug: Dilevalol 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 100 mg once daily for 6 weeks
Trial: 29380267
Drug: SUVN-502 200
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUVN-502 200 mg single dose
Trial: 29380267
Drug: SUVN-502 130
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUVN-502 130 mg once daily for 7 days
Trial: 29380267
Drug: SUVN-502 100
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUVN-502 100 mg once daily for 14 days
Trial: 29380267
Drug: SUVN-502 100
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUVN-502 100 mg single dose
Trial: 29380267
Drug: SUVN-502 50
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUVN-502 50 mg once daily for 7 days
Trial: 29380267
Drug: SUVN-502 50
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUVN-502 50 mg and 100 mg once daily
Trial: 25182248
Drug: High-intensity rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity rosuvastatin (40 mg/day) for 13 months
Trial: 23465742
Drug: Oestrogen patches
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen patches
Trial: 18434900
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy for strict blood glucose control to normoglycemia
Trial: 12517741
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE) at doses of 25, 50, 125, 300, or 600 mg/wk for 20 weeks
Trial: 10719857
Drug: Intrathecal bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal bolus injections of baclofen
Trial: 10719857
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of baclofen
Trial: 3542445
Drug: Acarbose 400
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose 400 mg
Trial: 3542445
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg (after one week of administration)
Trial: 3542445
Drug: Acarbose (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose (all doses tested)
Trial: 24072337
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day rosuvastatin
Trial: 28669329
Drug: 20-40 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-40 mg/day rosuvastatin
Trial: 23999037
Drug: Olmesartan/Amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olmesartan/Amlodipine combination (20/5mg)
Trial: 22417131
Drug: Intensive long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive long-term step-down treatment program (short-term day hospital treatment followed by combined group and individual psychotherapy)
Trial: 12966418
Drug: Supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive care (SC) with concomitant chemotherapy
Trial: 12966418
Drug: Cisplatin-based treatment
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based treatment
Trial: 8787869
Drug: Ciprofloxacin given
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin given orally (500 mg) alone
Trial: 8787869
Drug: Ciprofloxacin given
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin given orally (500 mg) plus enteral feeding (Sustacal)
Trial: 8787869
Drug: Ciprofloxacin given
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin given via gastrostomy tube (500 mg crushed in 60 ml water)
Trial: 8787869
Drug: Ciprofloxacin given
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin given via gastrostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Trial: 8787869
Drug: Ciprofloxacin given
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin given via jejunostomy tube (500 mg crushed)
Trial: 8787869
Drug: Ciprofloxacin given
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin given via jejunostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Trial: 1454432
Drug: Cefixime (CFX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (CFX), 8 mg/kg once daily
Trial: 1454432
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (PEN), 250 mg 3 times daily
Trial: 3906248
Drug: Naftidrofuryl 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftidrofuryl 600 mg daily for six months
Trial: 24827384
Drug: Palmitoylethanolamide (PEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoylethanolamide (PEA) 300mg tablets, two times per day for six months
Trial: 20538235
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg tramadol (Group T)
Trial: 20538235
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg tramadol plus 1 g of paracetamol (Group P)
Trial: 18165641
Drug: PCB (Bevacizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCB (Bevacizumab in combination with carboplatin and paclitaxel)
Trial: 15906418
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg (Blosart, Julphar, UAE)
Trial: 15906418
Drug: Losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 50 mg (Cozaar, MSD, The Netherlands)
Trial: 7027708
Drug: Progestogen only
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogen only (Lynestrenol 0.5 mg daily)
Trial: 7027708
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (Ethinyl oestradiol 50 μg + lynestrenol 2.5 mg)
Trial: 28950844
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/d for 2 weeks before surgery
Trial: 27422275
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) programme, one session every 2 weeks for 10 weeks, with telephone contact every 2 weeks
Trial: 27422275
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour therapy (CBT) programme
Trial: 15333719
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no added gelling agent)
Trial: 12587625
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ornidazole 30 mg/kg
Trial: 12587625
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ornidazole 25 mg/kg
Trial: 12587625
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ornidazole 20 mg/kg
Trial: 12587625
Drug: Ornidazole 25
RxNorm normalized name: ornidazol
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole 25 mg/kg per day for 5 days
Trial: 12587625
Drug: Metronidazole 20
RxNorm normalized name: metronidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 20 mg/kg per day for 7 days
Trial: 9691361
Drug: Intravenous anti-D
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anti-D (200 micrograms)
Trial: 9691361
Drug: Intramuscular anti-D
RxNorm normalized name: anti-D (rh) immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular anti-D (200 micrograms)
Trial: 9691361
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous and intramuscular anti-D
Trial: 2527132
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g day‐1 of crystalline fructose in divided amounts as part of their isocaloric diet
Trial: 2527132
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g day‐1 of crystalline fructose
Trial: 402088
Drug: 600 gm/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 gm/24 hours combination of glucose, fructose, and xylitol
Trial: 31649219
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) at 2.4 ATA for 90 minutes in addition to conventional wound care
Trial: 29281988
Drug: Intravenous artesunate
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous artesunate (AS)
Trial: 29281988
Drug: Intravenous quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous quinine (QNN)
Trial: 29281988
Drug: ACT administered
RxNorm normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT administered
Trial: 26005259
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac + oral B vitamin
Trial: 26005259
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac + oral vitamin E
Trial: 26005259
Drug: Oral diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diclofenac + placebo
Trial: 23503879
Drug: PCNL as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCNL as first treatment (group 2)
Trial: 19451765
Drug: 1.8 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 g/d omega-3
Trial: 15138617
Drug: 600 ml
RxNorm normalized name: urinary bag 600 mL-10" MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 ml coffee/day and a supplement of 200 microg folic acid/d
Trial: 9650545
Drug: Intravenous terazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terazosin (7.5 mg)
Trial: 9650545
Drug: Oral terazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terazosin (1 mg on day 1, 2 mg on day 2, and 5 mg on days 3 and 4)
Trial: 9650545
Drug: Intravenous terazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terazosin (2.5 mg, 5 mg, or 7.5 mg)
Trial: 9650545
Drug: Intravenous terazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous terazosin
Trial: 9650545
Drug: Oral terazosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terazosin
Trial: 8031158
Drug: UFT group
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT group (300 mg/day for one year)
Trial: 8031158
Drug: non-treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-treatment group
Trial: 2688079
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg tenoxicam once-daily
Trial: 2688079
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ketoprofen b.i.d.
Trial: 31968595
Drug: Preoperative whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative whey protein-infused carbohydrate loading and postoperative early oral feeding (CHO-P)
Trial: 27765310
Drug: Intravascular ultrasound
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravascular ultrasound using the CardioProlific Genesis System followed by local administration of a liquid mixture of iopromide 370 and paclitaxel 1.0 μg/mm3